Abstract
AimChronic prostatitis/Chronic pelvic pain syndrome (CP/CPPS) is a chronic disease with an unknown etiology and characterize with urinary sensibility, pelvic and genitoperineal pain. No effective treatment regime is described in the literature. In this present study, the efficacy of selective cyclooxygenase type-II (COX-II) inhibitor (rofecoxib), α-1 blocker (doxazosin) and their combination treatments were evaluated.MethodsSixty-eight patients (mean age: 40.3 ± 8.2 years; range:22–54), were enrolled to the study. Twenty-four, 21 and 23 patients were treated with rofecoxib (50 mg/day), doxazosin (4 mg/day), and their combinations, respectively. The efficacies of these regimens were evaluated by comparing pre and post-treatment National Institutes of Health–Chronic Prostatitis Symptom Index (NIH-CPSI) scores as well as number of patients whose total scores decreased 25%.ResultsThere was significant improvement in total NIH-CPSI scores with rofecoxib treatment than doxazosin (14.3 ± 5.3 vs. 9.5 ± 5.8, p:0.0249). Addition of doxazosin,, to rofecoxib treatment couldn’t provide an additional benefit to rofecoxib treatment alone (13.6 ± 5.8 vs. 14.3 ± 5.3, p:0.9856). More than 25% improvement in total symptom score was significantly more in rofecoxib and rofecoxib+doxazosin combination than doxazosin alone (P < 0.05).ConclusionTreatment with rofecoxib at CP/CPPS is effective. Addition of doxazosine to rofecoxib didn’t improve symptoms. Since 2004, COX-II inhibitors aren’t in use cause of cardiovascular side effects. We need anti-inflammatory drugs as effective as COX-II inhibitors. They can be used at patients with low cardiovascular risk, who couldn’t be treated with other several treatments. To investigate the optimal therapy for CP/CPPS further long term researches with large populations should be performed.
Keywords
Additional Information
Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.
Rights and Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/
About This Article
How to Cite This Article
Mutlu Ateş, Mustafa Karalar, Bünyamin Yıldırım, Fatih Pektaş, Cemil Ay, Mehmet Baykara, Tibet Erdoğru. The effect of rofecoxib/doxazosin treatment for chronic prostatitis/chronic pelvic pain syndrome in men. J Clin Anal Med 2012;3(3):275-278. doi:10.4328/JCAM.680
Publication History
- Received:
- 20.04.2011
- Accepted:
- 04.05.2011
- Published Online:
- 01.07.2012
- Printed:
- 01.07.2012